Bionano Genomics CEO Erik Holmlin terminated; Chairman Al Luderer named interim CEO

Bionano Genomics, Inc.

CEO Erik Holmlin terminated effective May 5, 2026; will serve as advisor under consulting agreement.
Board appoints Chairman Albert Luderer as interim CEO and interim principal financial officer.
Luderer receives $600k base salary, up to $400k bonus, and $4k/month housing/travel stipend.
Chris Twomey appointed Lead Independent Director to support governance during transition.
Company will immediately commence search for a permanent CEO.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Albert A. Luderer

Interim Chief Executive Officer

BNGO · Bionano Genomics, Inc.

Effective: 2026-05-05
Filed: May 6, 2026, 7:59 PM ET

As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company’s Chairman of the Board, as the Company’s Interim Chief Executive Officer.

Departed

Erik Holmlin

President and Chief Executive Officer

BNGO · Bionano Genomics, Inc.

Effective: 2026-05-05
Successor: Albert A. Luderer
Filed: May 6, 2026, 7:59 PM ET

On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Albert A. Luderer was appointed as Interim Chief Executive Officer at Bionano Genomics, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company’s Chairman of the Board, as the Company’s Interim Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Erik Holmlin was terminated as President and Chief Executive Officer at Bionano Genomics, Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately.

View on SEC.gov

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001411690-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.